Why the study?
Does neferine pre-treatment prevent doxorubicin-induced cardiotoxicity in H9c2 cardiomyoblasts?
Does neferine pre-treatment prevent doxorubicin-induced cardiotoxicity in H9c2 cardiomyoblasts?
Neferine shows potential in ameliorating doxorubicin-mediated cardiotoxicity through modulation of IGF-1R/Nrf2 signaling in a preclinical cell model.
Suggests a potential cardioprotective mechanism against doxorubicin toxicity; leaves open.
Doxorubicin (DOX) induced cardiotoxicity is a major problem during chemotherapy of cancers. DOX-mediated suppression of type 1 IGF receptor (IGF-1R) signaling leads to cardiac dysfunction. Neferine, a bisbezylisoquinoline alkaloid from the seed embryos of Nelumbo nucifera Gaertn possesses a distinct range of pharmacological properties. Herewith, the present study attempts to elucidate the protective role of neferine against DOX induced toxicity in H9c2 rat cardiomyoblast cell line model. DOX-treated H9c2 cells significantly increased mitochondrial superoxide generation, depleted cellular antioxidant status, suppressed the activation of IGF-1R signaling via PI3K/Akt/mTOR and induced autophagy by the activation of ULK1, Beclin1, Atg7, and LC3B. Neferine pre-treatment activated IGF-1R signaling, improved cellular antioxidant pool, increased the expression of down-stream targets of IGF-1R, such as PI3K/Akt/mTOR, inhibited mitochondrial superoxide generation and autophagy significantly with the induction of Nrf2 translocation and expressions of HO1 and SOD1. Our study suggests the use of neferine for amelioration of DOX-mediated cardiotoxicity.
No takes yet. Share an insight, caveat, or question.
Priya et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: